ArticleBMC public health2024
Cystatin C and sarcopenia index are associated with cardiovascular and all-cause death among adults in the United States.
Article in BMC public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Revisiting the Sarcopenic Index in Older Adults with Reduced Kidney Function: Association with EWGSOP2-Defined Probable Sarcopenia.Journal of clinical medicine · 2026Article
- Normalized creatinine-to-cystatin C ratio and cardiovascular disease risk in populations with cardiovascular-kidney-metabolic syndrome stages 0-3: findings from a national and prospective cohort study.European journal of medical research · 2026Article
- Association Between Sarcopenic Obesity-Related Scores and Liver Fibrosis in Patients with Steatotic Liver Disease: A Cross-Sectional Study.Diagnostics (Basel, Switzerland) · 2026Article
- Risk of Cardiovascular Disease Mortality in Patients With Diagnosed Cancer and Associated Genetic and Proteomic Mechanisms: A UK Biobank-Based Cohort Study.Journal of the American Heart Association · 2026Article
- Association of the sarcopenia index with incident depressive symptoms and adverse depressive symptom trajectories.Frontiers in nutrition · 2026Article
- Multimodal AI Model for Sarcopenia Detection: Integrating Chest CT and Clinical Parameters in Older Adults.Clinical interventions in aging · 2026Article
- Association between triglyceride-glucose muscle-loss index (TyG-MLI) and incident cardiovascular disease: a prospective cohort study in the UK biobank.Cardiovascular diabetology · 2025Article
- Cystatin C for gentamicin dosing - a case study.Biochemia medica · 2025Article
- Association between high-sensitivity C-reactive protein, cystatin C and all-cause mortality in middle-aged and elderly participants with sarcopenia.Aging clinical and experimental research · 2025Article
- Development and Validation of a Predictive Model for Activities of Daily Living Dysfunction in Older Adults: Retrospective Analysis of Data From the China Health and Retirement Longitudinal Study.JMIR medical informatics · 2025Article
- Monitoring Sarcopenia With Incretin Receptor Activator Treatment.Journal of diabetes · 2025Article
- Association Between the Serum Creatinine to Cystatin C Ratio and Cardiovascular Disease in Middle-Aged and Older Adults in China: A Nationwide Cohort Study.Journal of the American Heart Association · 2025Article
- Association between serum cystatin C and chronic lung disease in middle-aged and elderly Chinese: a CHARLS cross-sectional study.Scientific reports · 2025Article
- Impact of the hemoglobin-to-red cell distribution width ratio on 30-day readmission in patients with heart failure.BMC cardiovascular disorders · 2025Article
- An explainable machine learning-based prediction model for sarcopenia in elderly Chinese people with knee osteoarthritis.Aging clinical and experimental research · 2025Article
- Sex differences in the association between sarcopenia index and sarcopenia: a cross-sectional study from a Chinese community-based population.European geriatric medicine · 2025Article
- The association of HALP score with low muscle mass in older adults.Frontiers in nutrition · 2025Article
- Sex-specific prognostic utility of the sarcopenia index in all-cause mortality risk for patients with heart failure.Frontiers in nutrition · 2025Article
- Serum creatinine to cystatin C ratio in relation to heart failure with preserved ejection fraction.BMC cardiovascular disorders · 2024Article
- Sarcopenia.Journal of diabetes · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesThis study aimed to investigate the association of cystatin C, serum creatinine and sarcopenia index with cardiovascular and all-cause death in general population.
methodsData of participants from the National Health and Nutrition Examination Surveys (NHANES) from 1999 to 2004 were used and all participants were followed up regularly until December 31, 2019. Multivariable Cox analysis was used to investigate the association of cystatin C, serum creatinine and sarcopenia index with cardiovascular and all-cause death. Restricted cubic spline was conducted to evaluate the nonlinear association.
resultsA total of 9894 participants with a mean age of 45.64 years were enrolled and followed up for a mean duration of 15.62 ± 4.68 years. Approximately 50.3% were male and there were a total of 2681 all-cause deaths and 691 cardiovascular deaths recorded during the follow-up period. In final adjusted model, compared with the first quartile of cystatin C (< 0.659 mg/L), the risk of cardiovascular and all-cause death increased 2.36-fold and 1.71-fold for participants in the fourth quartile (≥ 0.877 mg/L) (HR: 3.36, 95% CI: 2.06-5.46, P < 0.001; HR: 2.71, 95% CI: 2.17-3.38, P < 0.001; respectively). Furthermore, a higher sarcopenia index (< 88.41 vs. ≥125.52) was associated with the reduced risk of cardiovascular death (HR: 0.41, 95% CI: 0.31-0.53, P < 0.001) as well as all-cause death (HR: 0.41, 95% CI: 0.35-0.49, P < 0.001). Additionally, restricted cubic splines showed that there was a nonlinear relationship between sarcopenia index levels and all-cause death while there was a linear relationship between sarcopenia index levels and cardiovascular death.
conclusionsHigher sarcopenia index was associated with the decreased risk of cardiovascular and all-cause death in general population in the United States. Elevated cystatin C was positively associated with cardiovascular and all-cause death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.